Detalhe da pesquisa
1.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
J Neurol Neurosurg Psychiatry
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38569872
2.
Cognitive outcomes in Susac syndrome: A 2-year neuropsychological follow-up study.
Eur J Neurol
; 31(4): e16186, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308420
3.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler
; 29(7): 875-883, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36851894
4.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler
; 28(6): 958-969, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34623947
5.
Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors.
Eur J Neurol
; 28(12): 4209-4213, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34374173
6.
Inter-assay diagnostic accuracy of cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis.
Front Immunol
; 15: 1385231, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38745673
7.
Multiple Sclerosis Multidisciplinary Care: A National Survey and Lessons for the Global Community.
Mult Scler Relat Disord
; 85: 105540, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38489948
8.
Atypical clinical and novel radiological findings in Susac syndrome: Experience from a large monocentric cohort.
J Neuroimmunol
; 376: 578032, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36736020
9.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
JAMA Neurol
; 80(8): 789-797, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307006
10.
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
JAMA Neurol
; 80(7): 739-748, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37273217
11.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
JAMA Neurol
; 80(7): 702-713, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37437240
12.
Lifestyle factors in multiple sclerosis disability progression and silent brain damage: A cross-sectional study.
Mult Scler Relat Disord
; 65: 104016, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35809391